Liraglutide Explored for Sleep Apnea and Quality of Life in Obese COPD Patients

Obesity is a major risk factor for Obstructive Sleep Apnea (OSA) and can significantly exacerbate Chronic Obstructive Pulmonary Disease (COPD), leading to a substantial decline in health-related quality of life (HRQoL). Current therapeutic strategies often target these conditions individually, overlooking their complex interconnections. This study addresses the knowledge gap by exploring whether liraglutide, a GLP-1 receptor agonist known for its weight-reducing effects, can simultaneously improve OSA severity and HRQoL in individuals suffering from both obesity and COPD.

The liraglutide group demonstrated a significant mean body weight reduction of -6.5 kg (or -6.0% of baseline weight) compared to a modest -1.2 kg in the placebo group (p<0.001). Concurrently, OSA severity, as quantified by the AHI (apnea-hypopnea index, a measure of breathing interruptions during sleep), improved significantly in the liraglutide group, showing a mean reduction of 8.2 events/hour versus 1.5 events/hour in the placebo group (p=0.007). > The most impactful finding was a 43% reduction in the proportion of patients classified with severe OSA (AHI > 30 events/hour) in the liraglutide group, compared to only a 10% reduction in the placebo group (p=0.02). Furthermore, improvements in HRQoL were evident, with the liraglutide group experiencing a 5.8-point increase in the SF-36 physical component summary score compared to a 1.1-point increase in the placebo group (p=0.015). COPD-related symptoms also improved, indicated by a mean -4.5 point reduction in the SGRQ score in the liraglutide group, signifying better respiratory health (p=0.03).